Novo Nordisk expects to cover demand for obesity drug in 2022

It will take time before Novo Nordisk can keep up with the demand for obesity drug Wegovy, launched in the US in June. The supply issue is our top priority, says the CEO.

Photo: Jacob Gronholt-Pedersen/Reuters/Ritzau Scanpix

The demand for obesity drug Wegovy in the US has taken Novo Nordisk by surprise, and the pharmaceutical company is struggling to keep up, acknowledged CEO Lars Fruergaard Jørgensen in the second quarter report released a few weeks ago.

Now, however, Danish business media Børsen reports that the pharma company cannot foresee supply stabilizing until 2022, confirmed in a product supply update by Novo Nordisk.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs